Mark Fielden active positions
| Companies | Position | Start | End |
|---|---|---|---|
Kate Therapeutics, Inc.
 Kate Therapeutics, Inc. BiotechnologyHealth Technology The American company is focused on developing gene therapies to treat muscle and heart diseases using adeno-associated virus (AAV) technology. Kate Therapeutics is applying novel technology platforms to address the limitations of current gene therapies, including tissue-specific delivery and gene regulation. The company's breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. The company was founded by Eric Wang, Mark Fielden, Alan H. Beggs, Sharif Tabebordbar, Kevin M. Forrest, and Kevin M. Forrest has been the CEO since incorporation. | Founder | 2020-12-31 | - |
| Corporate Officer/Principal | 2020-12-31 | - |
Career history of Mark Fielden
Statistics
International
| United States | 2 |
Operational
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Kate Therapeutics, Inc.
Kate Therapeutics, Inc. BiotechnologyHealth Technology The American company is focused on developing gene therapies to treat muscle and heart diseases using adeno-associated virus (AAV) technology. Kate Therapeutics is applying novel technology platforms to address the limitations of current gene therapies, including tissue-specific delivery and gene regulation. The company's breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. The company was founded by Eric Wang, Mark Fielden, Alan H. Beggs, Sharif Tabebordbar, Kevin M. Forrest, and Kevin M. Forrest has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Mark Fielden
- Experience
